Wednesday August 23rd 2017

IQWiG study finds no added benefit of teriflunomide

Teriflunomide (trade name: Aubagio) has been approved in Germany since August 2013 for adults with relapsing remitting multiple sclerosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).

This article is from: 

IQWiG study finds no added benefit of teriflunomide

Leave a Comment

More from category

Novartis launches MS study using data collected from smartphones
Novartis launches MS study using data collected from smartphones

Novartis (NYSE:NVS) said today that it is launching a research study to better understand the daily challenges facing [Read More]

McDonald criteria: MS diagnosis guidelines
McDonald criteria: MS diagnosis guidelines

Learn about the McDonald criteria. What is dissemination in space, what is dissemination in time, and what additional [Read More]

Multiple sclerosis: Are we close to a cure?
Multiple sclerosis: Are we close to a cure?

Read this article: Multiple sclerosis: Are we close to a cure? [Read More]

Medical News Today: McDonald criteria: MS diagnosis guidelines
Medical News Today: McDonald criteria: MS diagnosis guidelines

Learn about the McDonald criteria. What is dissemination in space, what is dissemination in time, and what additional [Read More]

Medical News Today: Multiple sclerosis: Are we close to a cure?
Medical News Today: Multiple sclerosis: Are we close to a cure?

Discoveries and breakthroughs in multiple sclerosis research are building momentum, but just how close are we to [Read More]